VERTEX PHARMACEUTICALS INC / MA — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+9.5% +$278M
$3.19B
Cost of Revenue↑+10.1% +$43M
$466M
R&D↓-2.5% -$25M
$974M
SG&A↑+29.0% +$109M
$487M
D&A↑+19.8% +$9M
$56M
Operating Income
$1.21B
EBITDA↑+2613.1% +$1.22B
$1.26B
Interest Expense↑+17.9% +$500K
$3M
Interest Income
—
Other Income/Expense
$128M
Pretax Income
$1.33B
Tax Provision↓-37.4% -$84M
$140M
Net Income
$1.19B
Operating Margin
37.8%
Net Margin
37.3%
Effective Tax Rate
10.5%
Deferred Tax Assets↑+82.9% +$102M
$226M
Deferred Tax Liabilities
—
DTA Valuation Allowance↑+78.7% +$53M
$121M
Tax Credit Carryforwards↑+24.2% +$58M
$296M
NOL Carryforwards
—
ETR (Continuing Operations)↓-300.6pts
14.9%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-29.5pts
0.0%
ETR Foreign Differential (pp)
21.3%
Operating Lease Cost
$1.29B
Revenue YoY Variation↓-6.1pts
9.5%
Income YoY Variation↓-1.3pts
6.3%
Revenue QoQ Variation↓-1.4pts
3.7%
Income QoQ Variation
1.7%